Compositions, methods and kits for treating leukemia

摘要

The disclosure relates to a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a first anti-cancer drug consisting of: isolated or synthesized delta12-prostaglandin J3 (delta12-PGJ3 - see abstract drawing) for inhibiting leukaemia stem cell (LSC) growth. The composition may further have a second anti-cancer drug, which may be imatinib. The disclosure also relates to the use of a composition comprising a pharmaceutically acceptable carrier and at least a first anti-cancer drug selected from isolated or synthesized delta12-PGJ3 in a therapeutically effective amount for inducing death of LSCs in the subject thereby treating leukaemia.